Chris Roberts jumps back into biotech with CSO gig at Black Diamond; Troubled Five Prime appoints interim CEO
→ After spending two years as entrepreneur-in-residence at SR One — the venture arm of his former employer, GlaxoSmithKline — Chris Roberts is back at the frontlines of biotech.
As CSO of Black Diamond Therapeutics, Roberts joins CEO David Epstein in driving their targeted kinase inhibitors toward the clinic. He will lead research and early development on the biotech’s MAP platform, which zeroes in on allosteric mutations of oncogenes. Its lead candidate, BDTX-189, targets EGFR and HER2 regardless of tumor type.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters